Andrew V Schally

Professor at Microbiology and Immunology, University of Miami0 Followers

Dr. Andrew V. Schally is well-respected in the field of medical research, serving as a distinguished Leonard M. Miller Professor and a leading figure in the scientific community. As the head of the Endocrine Polypeptide and Cancer Institute at the VAMC, Dr. Schally has made significant contributions to the understanding and treatment of endocrine-related cancers. His work in pathology and laboratory medicine has been instrumental in advancing research methodologies and therapeutic approaches. Throughout his illustrious career, Dr. Schally has been recognized for his pioneering research and dedication to improving patient outcomes. His leadership at the institute has fostered a collaborative environment that encourages innovation and excellence in scientific inquiry. Dr. Schally's commitment to education and mentorship has also inspired a new generation of researchers, ensuring the continued advancement of medical science.

Research Interests

Endocrine-related cancers pathology laboratory medicine cancer research endocrine polypeptides therapeutic approaches medical research scientific inquiry

Publications

1 - Abstract 2125: AN-162, a targeted cytotoxic analog of somatostatin, suppresses growth of human hormone refractory prostate cancers in vitro and in vivo.,Cancer Research

Ferenc G. Rick , Andrew Abi-Chaker , Luca Szalontay , Norman L. Block , Gabor Halmos , Andrew V. Schally ,

, 2125-2125, 2013-04-01

2 - Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia‐induced oxidative stress and cognitive deficits in mouse,Journal of Neurochemistry

Deepti Nair , Vijay Ramesh , Richard C. Li , Andrew V. Schally , David Gozal ,

, 531-540, 2013-07-19

3 - Abstract 4769: Growth hormone-releasing hormone (GHRH) antagonist attenuates cell motility of human endometrial cancer by down-regulating Twist and N-Cadherin expression.,Cancer Research

Hsien-Ming Wu , Andrew V. Schally , Peter C.K. Leung ,

, 4769-4769, 2013-04-01

4 - Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75),European Journal of Endocrinology

David Gonzalez-Barcena , Manuel Vadillo Buenfil , Emilo Garcia Procel , Laura Guerra-Arguero , Imelda Cardenas Cornejo , Ana Maria Comaru-Schally , Andrew V Schally ,

, 286-292, 1994-09-01

5 - LHRH receptor expression in sarcomas of bone and soft tissue,Hormone Molecular Biology and Clinical Investigation

Chenthuran Deivaraju , H. Thomas Temple , Norman Block , Philip Robinson , Andrew V. Schally ,

, 105-111, 2016-09-17

6 - Response of patients with advanced prostatic cancer to administration of somatostatin analog RC‐160 (vapreotide) at the time of relapse,The Prostate

David González Barcena , Andrew V. Schally , Manuel Vadillo Buenfil , Adolfo Cortez Morales , Victor Hernández L , Imelda Cardenas‐Cornejo , Ana Maria Comaru Schally ,

, 183-191, 2003-05-20

7 - Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095,Proceedings of the National Academy of Sciences

Gabor Halmos , Andrew V. Schally ,

, 956-960, 1997-02-04

8 - Synthesis and in vitro and in vivo activity of analogs of growth hormone‐releasing hormone (GH‐RH) with C‐terminal agmatine,International Journal of Peptide and Protein Research

MARTA ZARANDI , VALER CSERNUS , LAZARO BOKSER , SANDOR BAJUSZ , KATE GROOT , ANDREW V. SCHALLY ,

, 499-505, 1990-12-01

9 - Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer,Applied Immunohistochemistry & Molecular Morphology

Mahsa Khanlari , Andrew V. Schally , Norman L. Block , Mehrdad Nadji ,

, 1-5, 2018-01-01

10 - Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer,Journal of Clinical Laboratory Analysis

Matyas Fekete , James L. Wittliff , Andrew V. Schally ,

, 137-147, 1989-01-01

11 - Receptors for luteinizing hormone‐releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia,The Prostate

Matyas Fekete , Tommie W. Redding , Ana Maria Comaru‐Schally , J. Edson Pontes , Robert W. Connelly , Gordan Srkalovic , Andrew V. Schally ,

, 191-208, 1989-01-01

12 - Abstract 4620: Exploring the role of GHRH antagonist MIA-602 in overcoming doxorubicin resistance in acute myeloid leukemia,Cancer Research

Simonetta I. Gaumond , Joel Costoya , Andrew V. Schally , Joaquin J. Jimenez ,

, 4620-4620, 2024-03-22

13 - Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells,The Prostate

Herta Reile , Patricia E. Armatis , Andrew V. Schally ,

, 29-38, 1994-07-01

14 - Growth hormone‐releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan‐induced chronic prostatitis,The Prostate

Petra Popovics , Renzhi Cai , Wei Sha , Ferenc G. Rick , Andrew V. Schally ,

, 970-980, 2018-05-21

15 - Recovery of Pituitary‐Gonadal Function in Male Rats after Long‐Term Suppression Induced by a Single Injection of Microcapsules of LH‐RH Antagonist Cetrorelix (SB‐75),Journal of Andrology

JACEK PINSKI , TETSU YANO , KAROLY SZEPESHAZI , KATE GROOT , ANDREW V. SCHALLY ,

, 164-169, 1993-05-06

16 - Differential immunostaining of various types of breast carcinomas for growth hormone‐releasing hormone receptor – Apocrine epithelium and carcinomas emerging as uniformly positive,APMIS

Bence Kővári , Orsolya Rusz , Andrew V. Schally , Zsuzsanna Kahán , Gábor Cserni ,

, 824-831, 2014-01-31

Share Andrew's Profile